Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

What kind of PhI­Ib da­ta is worth $4B cash? Take­da’s Andy Plump has some thoughts on that

A few months back, when Take­da caused jaws to drop with its eye-wa­ter­ing $4 bil­lion cash up­front for a mid-stage TYK2 drug from Nim­bus, it had al­ready tak­en a deep dive on the sol­id Phase IIb da­ta Nim­bus had as­sem­bled from its dose-rang­ing study in pso­ri­a­sis.

Now, it’s rolling that da­ta out, ea­ger to demon­strate what in­spired the glob­al bio­phar­ma to go long in a neigh­bor­ing, but new, dis­ease are­na for the pipeline. And the most avid stu­dents of the num­bers will like­ly be at Bris­tol My­ers Squibb, who will have a mul­ti-year head start on pi­o­neer­ing the TYK2 space with So­tyk­tu (deu­cravac­i­tinib) as Take­da makes its lunge for best-in-class sta­tus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.